MYH9 and neoplasm: These results validated the critical role of the interactions among SPC25, MYH9, and RIOK1 in CDDP resistance in EOC, indicating that targeting the SPC25/RIOK1/MYH9 axis can inhibit tumor cell stemness and that it yields a potent anticancer efficacy when combined with CDDP.